15:26:46 EDT Mon 18 Oct 2021
Enter Symbol
or Name

Login ID:
Hemostemix Inc
Symbol HEM
Shares Issued 756,811,552
Close 2020-10-08 C$ 0.005
Recent Sedar Documents

ORIGINAL: Hemostemix wins motion to quash service re Aspire

2020-10-08 07:23 ET - News Release

Received by email:

File: '\\doc\emailin\20201008 032547 Attachment 2020 - 43 - News Release - Hemostemix Announces Win in Florida.docx'

CAN: 34494641.3

Hemostemix Announces Partial Win in Florida
Calgary, Alberta, October 8, 2020- Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV:HEM; OTC: HMTXF) is pleased t
--->o announce the Ninth Judicial Circuit Court for Orange County, Florida (the "Court") granted Hemostemix's motion to qu
--->ash service of process by Aspire Health Service, LLC ("Aspire") in Aspire's action filed against Hemostemix for declar
--->atory relief and specific performance in relation to the amended licensing agreement among Aspire and Hemostemix which
---> Hemostemix properly rescinded on December 5,   2019 . Aspire has 120 days to perfect service under the Hague Service 
--->Convention and file proof of service, failing which the complaint against Hemostemix will be dismissed without prejudi
The Company's motion to dismiss Aspire's claims on jurisdictional and mandatory arbitration grounds was not granted. T
--->he Order is immediately appealable and on Friday October 2, 2020, Hemostemix filed both a notice of appeal of the Cour
--->t's order and a motion to stay the proceedings in the Florida action, pending the appeal. 

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology 
--->Pioneer Award, Hemostemix developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angi
--->na, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat ov
--->er 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and effic
--->acy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from ampu
On October 21, 2019, Hemostemix announced the results from its Phase II CLI trial abstract entitled "Autologous Stem C
--->ell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Ye
--->ar Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outc
--->omes maintained for up to 4.5 years.  
Hemostemix owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with
---> Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, pleas
--->e visit www.hemostemix.com. 
Contact: Thomas Smeenk, President, CEO & Co-Founder
TSmeenk@Hemostemix.com   905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of th
--->e TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable
---> Canadian securities legislation. All statements, other than statements of historical fact, included herein are forwar
--->d-looking information. In particular, this news release contains forward-looking information  in relation to: the comm
--->ercialization of ACP-01. There can be no assurances that such forward-looking information will prove to be accurate, a
--->nd actual results and future events could differ materially from those anticipated in such forward-looking information
--->.  This forward-looking information reflects Hemostemix's current beliefs and is based on information currently availa
--->ble to Hemostemix and on assumptions which Hemostemix believes are reasonable. These assumptions include, but are not 
--->limited to: the underlying value of Hemostemix and its common shares; the successful resolution of the litigation that
---> Hemostemix is pursuing or defending (the "Litigation"); the timing of receipt of its full and complete clinical trial
--->s data; the results of ACP-01 research, trials and studies being equivalent to or better than previous research, trial
--->s or studies as well as management's expectations of anticipated results; Hemostemix's general and administrative cost
--->s remaining constant; the receipt of all required regulatory approvals for research, trials or studies as well as any 
--->required or desired financings of Hemostemix , including TSX Venture Exchange acceptance and any third party consents;
---> the level of activity, market acceptance and market trends in the healthcare sector; the  economy generally; consumer
---> interest in Hemostemix's services and products; competition and  Hemostemix's competitive advantages; and obtaining s
--->atisfactory financing to fund Hemostemix's operations including any research, trials or studies and the Litigation. Fo
--->rward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the ac
--->tual results, level of activity, performance or achievements of Hemostemix to be materially different from those expre
--->ssed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to:
---> the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory futility analysis and t
--->he results of such and future clinical trials; litigation and potential litigation that Hemostemix may face; general b
--->usiness, economic, competitive, political and social uncertainties; general capital market conditions and market price
--->s for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations i
--->ncluding the actual results of future research, trials or studies; competition; changes  in legislation affecting Hemo
--->stemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and futu
--->re developments in the Company's markets and the markets in which it expects to compete;  lack of qualified, skilled l
--->abour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders
---> and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures
--->, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social dis
--->tancing, disruptions to: markets, economic activity, financings, supply chains and sales channels, and a deterioration
---> of general economic conditions including a possible national or global recession or depression; the potential impact 
--->that the COVID-19 pandemic may have on Hemostemix may include a decreased demand for the services that Hemostemix offe
--->rs; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A des
--->cription of additional risk factors that may cause actual results to differ materially from forward-looking informatio
--->n  can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has at
--->tempted to identify important factors that could cause actual results to differ materially from those contained in for
--->ward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intende
--->d. Readers are cautioned that the foregoing list of factors is not exhaustive.  Readers are further cautioned not to p
--->lace undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectat
--->ions upon which they are placed will occur. Forward-looking information contained in this news release is expressly qu
--->alified by this cautionary statement. The forward-looking information contained in this news release represents the ex
--->pectations of Hemostemix as of the date  of this news release and, accordingly, it is subject to change after such dat
--->e. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking informa
--->tion, whether as a result of new information, future events or otherwise, except as expressly required by applicable s
--->ecurities law. 

© 2021 Canjex Publishing Ltd. All rights reserved.